Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer O n February 3, 2015, the US Food and Drug Administration (FDA) approved palbociclib in combination with letrozole for first-line treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. The combination was reviewed and approved 2 months ahead of schedule under the FDA's breakthrough therapy designation and priority review program. Palbociclib is an oral small molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6, while letrozole is an aromatase inhibitor (AI), a type of endocrine therapy that reduces circulating estrogen levels (see sidebar). The 2 agents were shown to have potentially synergistic tumor growth inhibitory activity in preclinical models of ER-positive breast cancer.
Approval was based on the finding of improved progressionfree survival (PFS) in the international, multicenter, open-label, randomized phase 2 PALOMA-1/TRIO-18 study. Between December 2009 and May 2012, 165 postmenopausal women aged 18 years or older with ER-positive, HER2-negative locally recurrent or unresectable breast cancer, were recruited from 50 sites in 12 countries. Patients were enrolled in 2 separate cohorts, sequentially, on the basis of ER-positive, HER2-negative status alone (cohort 1; n = 66) or in combination with cyclin D gene amplification or loss of p16 (cohort 2; n = 99). In both cohorts, patients were randomized 1:1 to 2.5 mg letrozole once daily alone (81 patients) or in combination with 125 mg palbociclib (84 patients) once daily for 3 weeks followed by 1 week off in 28-day cycles until disease progression, unacceptable toxicity, study withdrawal, or death.
Randomization was stratified by disease site (visceral, bone only, or other) and disease-free interval (>12 months from end of adjuvant treatment to recurrence compared with <12 months or de novo metastatic disease). Eligible patients were required to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) or bone-only disease with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and adequate organ function. Meanwhile, patients who were treated with neoadjuvant letrozole in the year before study enrollment, who had previously received CDK inhibitors, who had received any treatment for advanced breast cancer, or those with brain metastases were excluded.
A CT or MRI scan of the chest, abdomen, and pelvis; radiography of bone lesions; and clinical assessment of cutaneous disease were performed at screening and every 8 weeks. Bone scans were performed at baseline and every 12 weeks, and hematological and blood chemistry analyses were done every 2 weeks for the first 2 cycles and at the beginning of each cycle from then on.
The study population was generally balanced for baseline demographics and established prognostic factors, including age (median, 63 vs 64 years for cohorts 1 and 2, respectively) and ECOG performance status (0 in 55% and 56% and 1 in 45% and 44%, for cohorts 1 and 2, respectively), The agency approved a starting dose of palbociclib125 mg once daily taken with food for 21 days, followed by 7 days off treatment, repeating every 28 days along with letrozole 2.5 mg daily.
In the randomized phase 2 study that formed the basis of the approval, grade 3 (57%) or 4 (5%) decreased neutrophil counts were reported in 57% and 5%, respectively, of patients who received the palbociclib plus letrozole combination. Higher incidence of pulmonary embolism (PE) has been reported in 5% patients who were treated with palbociclib plus letrozole, compared with no cases among patients who were treated with letrozole alone. As such, patients should also be monitored for signs and symptoms of PE and treatedas medically appropriate.
Many ongoing and completed studies will help us to un- The PALOMA-1 study of palbociclib and letrozole provides proof-of-concept that the addition of a CDK4/6 inhibitor to an aromatase inhibitor, which blocks the activity of the enzyme aromatase that is responsible for converting androgens into estrogens, improves patient outcomes over letrozole alone.
Mechanistic analyses demonstrated that the combination enhances the phosphorylation of pRb, leading to a significant inhibition of downstream transcription factors such as E2F1 and FoxM, subsequent G1 cell cycle arrest, and reduced cell proliferation.
-Jane de Lartigue, PhD
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Inextricably linked CDK and ER pathways provide biological rationale
Figure reproduced and modified with permission from Dr RS Finn. He and Dr Slamon are investigators in the phase 3 confirmatory trial of palbociclib in over 600 women, which has completed enrollment, according to the UCLA release.
-Elizabeth Mechcatie
News angle
with a median duration of response of 20.3 months, and clinical benefit rate (in the ITT population). The study was not powered to detect overall survival (OS); few OS events had occurred at the time of final analysis, however, no detrimental effect on OS was observed. Although more patients experienced adverse events (AEs) in the combination arm compared with those who received letrozole monotherapy (all patients in the combination arm had at least 1 AE compared with 84% of patients treated with letrozole alone), the toxicity profile of the combination was found to be manageable and predictable. The most common AEs were neutropenia (28% and 6% of grade 3 and 4, respectively), leucopenia (19% grade 3), and fatigue (2% and 2%), but these were not associated with any serious clinical outcomes. Serious AEs included pulmonary embolism (4%), back pain (2%), and diarrhea (2%). The main reason for study discontinuation in both groups was disease progression (50% with the combination vs 70% for letrozole alone). AEs also resulted in dosage interruptions more frequently in the combination arm (33% vs 4%). There were no treatment-related deaths in either arm and combinatorial therapy was not associated with an increase in pain severity or pain on daily activity.
According to the prescribing information, the recommended starting dose of palbociclib in this setting is 125 mg once daily with food over a 28-day cycle (21 days on, 7 but there were slight imbalances in disease site, disease-free interval, and previous treatment.
The primary endpoint of the study was PFS and, as of final analysis in November 2013, over a median follow-up of 29.6 months for the combination arm and 27.9 months for the letrozole alone group, median PFS was 20.2 months compared with 10.2 months, respectively (hazard ratio [HR], 0.488; P = .0004). Initially, analysis of PFS was intended to be based on cohort 2 alone, however, an unplanned interim analysis of cohort 1 suggested that it was unlikely that additional patient selection based on cyclin D1 amplification or p16 loss would improve outcomes over the use of ER-positive, HER2-negative status alone. As a result, accrual into cohort 2 was halted and PFS analysis was based on combined data from both cohorts. The authors conclude that ER-positivity remains the best and most effective biomarker for patient selection in this setting. In cohort 1, median PFS was 26.1 months in the combination arm, compared with 5.7 months in the letrozole arm (HR, 0.299; P < .0001), whereas in cohort 2 it was 18.1 months compared with 11.2 months (HR, 0.508; P = .0046).
A number of secondary endpoints also demonstrated significant improvement in the combination arm, including objective response (in both the intent to treat [ITT] population and among those with measurable disease), days off ). Dose interruptions or delays and/or dose reductions or permanent discontinuation may be required for the management of some AEs, including grade 3 or 4 neutropenia and for coadministration with strong CYP3A inhibitors. The use of strong and moderate CYP3A inducers and strong CYP3A inhibitors should generally be avoided. Palbociclib can cause fetal harm and there are also warnings and precautions about the risk for infection and pulmonary embolism.
The approval of palbociclib and letrozole represents an important advancement for the treatment of ER-positive advanced breast cancer. Palbociclib, marketed as Ibrance by Pfizer, is the first in a new class of targeted therapy to gain regulatory approval and in this indication represents the first front-line treatment option to show improvement over endocrine therapy alone, the standard of care for this patient population. The phase 3 PALOMA-2 trial is currently ongoing (NCT01740427) to determine the effect of this combination on OS, with final data expected sometime in 2016, and several other phase 3 trials of palbociclib in combination with other forms of endocrine therapy are also ongoing.
